Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a Healthcare company (Biotechnology) with a market capitalization of $74M. The Maz Rating grades it against the other companies in its sector.
Tenaya Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.32, Tenaya Therapeutics, Inc. trades at 24.1x sales and 1.3x book value. Over the last twelve months it generated about $3M of revenue and a net loss of $113M. It runs an operating margin of -3446.6% and a net margin of -3356.8%. It shows return on equity of -115.2%, return on invested capital of -173.3% and a free cash flow yield of -100.4%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 3.78. Over the past 52 weeks the share price ranged from $0.30 to $1.46, with a beta of 2.88.
Tenaya Therapeutics, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Tenaya Therapeutics, Inc. (TNYA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 56.7% / 30% · Interest income / Revenue 37.4% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 56.4% / 33% · Receivables / Mkt Cap (36m) 0.48% / 49% · Interest income / Revenue 37.4% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 56.4% / 33.33% · Receivables / Mkt Cap (24m) 0.48% / 33.33% · Interest income / Revenue 37.4% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 72.2% / 33.33% · Receivables / Avg Assets (4Q) 2.56% / 33.33% · Interest income / Revenue 37.4% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 87.1% / 33.33% · (Cash+Recv) / Total Assets 87.9% / 33.33% · Interest income / Revenue 37.4% / 5% | Fail |
No. As of September 2026, Tenaya Therapeutics, Inc. (TNYA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Tenaya Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 37.4% of each dividend: Tenaya Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.